Skip to main content
SpringerLink
Log in

Kombinationstherapien zur Behandlung der AMD

  • Chapter
Altersabhängige Makuladegeneration

  • 1231 Accesses

Zusammenfassung

Die altersbedingte Makuladegeneration (AMD) ist die häufigste Erblindungsursache von Menschen über 50 Jahren in der westlichen Welt [1–3]. Die häufigste Ursache für einen gravierenden Verlust der Sehkraft bei AMD ist wiederum die Entstehung einer choroidalen Neovaskularisation (CNV), also die Ausbildung einer sog. exsudativen AMD (Synonyme: feuchte AMD, neovaskuläre AMD). Aufgrund der zunehmenden Lebenserwartung wird mit einem Anstieg der weltweiten Prävalenz der exsudativen AMD gerechnet [4]. Glücklicherweise gab es in jüngerer Zeit viele Fortschritte in der Behandlung der exsudativen AMD, wie z. B. die Einführung medikamentöser Therapien gegen CNV, die die Möglichkeiten zur Bekämpfung dieser verheerenden Erkrankung verbessert haben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Rubin GS, et al. (1994) Visual impairment and disability in older adults. Optometry & Vision Science 71(12): 750-60

    Article  CAS  Google Scholar 

  2. Williams RA, et al. (1998) The psychosocial impact of macular degeneration. Archives of Ophthalmology 116(4): 514-20

    PubMed  CAS  Google Scholar 

  3. Friedman DS, et al. (2004) Prevalence of age-related macular degeneration in the United States. Archives of Ophthalmology 122(4): 564-72

    Article  PubMed  Google Scholar 

  4. Kourlas H, et al. (2007) Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clinical Therapeutics 29(9): 1850-61

    Article  PubMed  CAS  Google Scholar 

  5. Klein R, et al. (1997) The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 104(1): 7-21

    PubMed  CAS  Google Scholar 

  6. Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Archives of Ophthalmology 122(4): 598-614

    Article  PubMed  Google Scholar 

  7. Pe’er J, et al. (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Laboratory Investigation 72(6): 638-45

    PubMed  Google Scholar 

  8. Grunwald JE, et al. (2005) Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Investigative Ophthalmology & Visual Science 46(3): 1033-8

    Article  Google Scholar 

  9. Yoshida S, et al. (2004) Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefes Archive for Clinical & Experimental Ophthalmology 242(5): 409-13

    Article  CAS  Google Scholar 

  10. Spaide RF (2006) Rationale for combination therapies for choroidal neovascularization. American Journal of Ophthalmology 141(1): 149-56

    Article  PubMed  Google Scholar 

  11. Gille J (2006) Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Experimental Dermatology 15(3): 175-86

    Article  PubMed  CAS  Google Scholar 

  12. Caprioni F, et al. (2007) Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncology 3(2): 141-8

    Article  PubMed  CAS  Google Scholar 

  13. Giaccone G (2007) The potential of antiangiogenic therapy in non-small cell lung cancer. Clinical Cancer Research 13(7): 1961-70

    Article  PubMed  CAS  Google Scholar 

  14. Mancuso A, et al. (2006) Current therapies and advances in the treatment of pancreatic cancer. Critical Reviews in Oncology-Hematology 58(3): 231-41

    Article  Google Scholar 

  15. Han ES, et al. (2007) Bevacizumab in the treatment of ovarian cancer. Expert Review of Anticancer Therapy 7(10): 1339-45

    Article  PubMed  CAS  Google Scholar 

  16. Taiwo BO (2006) Antiretroviral treatment: current approach and future prospects. African Journal of Medicine & Medical Sciences 35 Suppl: 1-11

    Google Scholar 

  17. Sturmer M, et al. (2007) Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. Antiviral Therapy 12(5): 695-703

    PubMed  Google Scholar 

  18. Weir MR (2008) Risk-based classification of hypertension and the role of combination therapy. Journal of Clinical Hypertension 10(1 Suppl 1): 4-12

    PubMed  Google Scholar 

  19. Elliott WJ (2008) What factors contribute to the inadequate control of elevated blood pressure? Journal of Clinical Hypertension 10(1 Suppl 1): 20-6

    PubMed  Google Scholar 

  20. Kaiser PK (2005) Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Current Medical Research & Opinion 21(5): 705-13

    Article  CAS  Google Scholar 

  21. Kaiser PK (2005) Steroids for choroidal neovascularization. American Journal of Ophthalmology 139(3): 533-5

    Article  PubMed  Google Scholar 

  22. Bandi N, et al. (2001) Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. European Journal of Pharmacology 425(2): 109-16

    Article  PubMed  CAS  Google Scholar 

  23. Folkman J, et al. (1987) Angiostatic steroids. Method of discovery and mechanism of action. Annals of Surgery 206(3): 374-83

    Article  PubMed  CAS  Google Scholar 

  24. Schmidt-Erfurth U, et al. (2000) Mechanisms of action of photodynamic therapy with verteporfin for the treatment of agerelated macular degeneration. Survey of Ophthalmology 45(3): 195-214

    Article  PubMed  CAS  Google Scholar 

  25. Schmidt-Erfurth U, et al. (1994) Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101(12): 1953-61

    PubMed  CAS  Google Scholar 

  26. Schlotzer-Schrehardt U, et al. (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Archive for Clinical & Experimental Ophthalmology 240(9): 748-57

    Article  CAS  Google Scholar 

  27. Schmidt-Erfurth U, et al. (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Investigative Ophthalmology & Visual Science 44(10): 4473-80

    Article  Google Scholar 

  28. Kaiser PK (2007) Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr Med Res Opin 23(3): 477-87

    Article  PubMed  CAS  Google Scholar 

  29. Verteporfin Roundtable (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25(2): 119-34

    Article  Google Scholar 

  30. Bressler NM, et al. (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Archives of Ophthalmology 119(2): 198-207

    PubMed  CAS  Google Scholar 

  31. Verteporfin In Photodynamic Therapy Study (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. American Journal of Ophthalmology 131(5): 541-60

    Article  Google Scholar 

  32. Azab M, et al. (2005) Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Archives of Ophthalmology 123(4): 448-57

    Article  PubMed  Google Scholar 

  33. Adamis AP, et al. (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina 25(2): 111-8

    Article  PubMed  Google Scholar 

  34. Gragoudas ES, et al. (2004) Pegaptanib for neovascular age-related macular degeneration. New England Journal of Medicine 351(27): 2805-16

    Article  PubMed  CAS  Google Scholar 

  35. Ruckman J, et al. (1998) 2’-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGFinduced vascular permeability through interactions requiring the exon 7-encoded domain. Journal of Biological Chemistry 273(32): 20556-67

    Article  PubMed  CAS  Google Scholar 

  36. Gaudreault J, et al. (2005) Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Investigative Ophthalmology & Visual Science 46(2): 726-33

    Article  Google Scholar 

  37. Rosenfeld PJ, et al. (2006) Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 355(14): 1419-31

    Article  PubMed  CAS  Google Scholar 

  38. Brown DM, et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14): 1432-44

    Article  PubMed  CAS  Google Scholar 

  39. Heier JS, et al. (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4): 633.e1-4

    Article  Google Scholar 

  40. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 350(23): 2335-42

    Article  PubMed  CAS  Google Scholar 

  41. Waisbourd M, et al. (2007) Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs & Aging 24(8): 643-62

    Article  CAS  Google Scholar 

  42. Avery RL, et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3): 363-372.e5

    Article  PubMed  Google Scholar 

  43. Bashshur ZF, et al. (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. American Journal of Ophthalmology 142(1): 1-9

    Article  PubMed  CAS  Google Scholar 

  44. Costa RA, et al. (2006) Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Investigative Ophthalmology & Visual Science 47(10): 4569-78

    Article  Google Scholar 

  45. Spaide RF, et al. (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26(4): 383-90

    Article  PubMed  Google Scholar 

  46. Rich RM, et al. (2006) Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26(5): 495-511

    Article  PubMed  Google Scholar 

  47. Slakter JS, et al. (2006) Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 113(1): 3-13

    Article  PubMed  Google Scholar 

  48. Clark AF (1997) AL-3789: a novel ophthalmic angiostatic steroid. Expert Opinion on Investigational Drugs 6(12): 1867-77

    Article  PubMed  CAS  Google Scholar 

  49. Kwak N, et al. (2000) VEGF is major stimulator in model of choroidal neovascularization. Investigative Ophthalmology & Visual Science 41(10): 3158-64

    CAS  Google Scholar 

  50. Shen J, et al. (2006) Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Therapy 13(3): 225-34

    Article  PubMed  CAS  Google Scholar 

  51. Ciulla TA, et al. (2003) Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 23(6): 808-14

    Article  PubMed  Google Scholar 

  52. Campochiaro PA, et al. (2006) Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Human Gene Therapy 17(2): 167-76

    Article  PubMed  CAS  Google Scholar 

  53. Raicu M, et al. (1993) Radiation damage to endothelial cells in vitro, as judged by the micronucleus assay. Mutagenesis 8(4): 335-9

    Article  PubMed  CAS  Google Scholar 

  54. Schilling H, et al. (1997) Long-term results after low dose ocular irradiation for choroidal haemangiomas. Br J Ophthalmol 81(4): 267-73

    Article  PubMed  CAS  Google Scholar 

  55. Verma L, et al. (2000) New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 48(4): 263-78

    PubMed  CAS  Google Scholar 

  56. Comer GM, et al. (2004) Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 21(15): 967-92

    Article  PubMed  CAS  Google Scholar 

  57. Zambarakji HJ, et al. (2006) Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology 113(11): 2012-9

    Article  PubMed  Google Scholar 

  58. Ciulla TA, Danis RP, Harris A (1998) Age-related macular degeneration: a review of experimental treatments. Surv Ophthalmol 43(2): 134-46

    Article  PubMed  CAS  Google Scholar 

  59. Parsons JT, et al. (1994) Radiation retinopathy after externalbeam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 30(4): 765-73

    PubMed  CAS  Google Scholar 

  60. Brown GC, et al. (1982) Radiation retinopathy. Ophthalmology 89(12): 1494-501

    PubMed  CAS  Google Scholar 

  61. Valmaggia C, Ries G, Ballinari P (2002) Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: a randomized clinical trial. Am J Ophthalmol 133(4): 521-9

    Article  PubMed  Google Scholar 

  62. Sivagnanavel V, et al. (2004) Radiotherapy for neovascular agerelated macular degeneration. Cochrane Database Syst Rev (4): CD004004

    PubMed  Google Scholar 

  63. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study) (1999) Radiation Therapy for Age-related Macular Degeneration. Ophthalmology 106(12): 2239-47

    Article  Google Scholar 

  64. Anders N, et al. (1998) [Radiotherapy of exudative senile macular degeneration. A prospective controlled study]. Ophthalmologe 95(11): 760-4

    Article  PubMed  CAS  Google Scholar 

  65. Eter N, Schuller H, Spitznas M (2001) Radiotherapy for agerelated macular degeneration: is there a benefit for classic CNV? Int Ophthalmol 24(1): 13-9

    Article  PubMed  CAS  Google Scholar 

  66. Bergink GJ, et al. (1998) A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: radiation versus observation. Graefes Arch Clin Exp Ophthalmol 236(5): 321-5

    Article  PubMed  CAS  Google Scholar 

  67. Char DH, et al. (1999) Randomized trial of radiation for agerelated macular degeneration. Am J Ophthalmol 127(5): 574-8

    Article  PubMed  CAS  Google Scholar 

  68. Ciulla TA, et al. (2002) Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol 134(6): 905-6

    Article  PubMed  Google Scholar 

  69. Marcus DM, et al. (2001) External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 2): 171-80

    Google Scholar 

  70. Kobayashi H (2000) Age-related macular degeneration: longterm results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol 130(5): 617-35

    Article  PubMed  CAS  Google Scholar 

  71. Hart PM, et al. (2002) Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for agerelated macular degeneration. Arch Ophthalmol 120(8): 1029-38

    PubMed  CAS  Google Scholar 

  72. Kacperek A, Briggs M, Sheen M, Damato BE, Errington RD, Harding S (2001) Macular degeneration treatment at Clatterbridge Centre for oncology: treatment and preliminary results. Physica Medica 17 (Suppl 3): 7-9

    Google Scholar 

  73. Postgens H, Bodanowitz S, Kroll P (1997) Low-dose radiation therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 235(10): 656-61

    Article  PubMed  CAS  Google Scholar 

  74. Spaide RF, et al. (1998) External beam radiation therapy for choroidal neovascularization. Ophthalmology 105(1): 24-30

    Article  PubMed  CAS  Google Scholar 

  75. Stalmans P, Leys A, Van Limbergen E (1997) External beam radiotherapy (20 Gy, 2 Gy fractions) fails to control the growth of choroidal neovascularization in age-related macular degeneration: a review of 111 cases. Retina 17(6): 481-92

    PubMed  CAS  Google Scholar 

  76. Marcus DM, et al. (2004) Radiotherapy for recurrent choroidal neovascularisation complicating age related macular degeneration. Br J Ophthalmol 88(1): 114-9

    Article  PubMed  CAS  Google Scholar 

  77. Marcus DM, et al. (2004) The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study. Am J Ophthalmol 138(5): 818-28

    Article  PubMed  Google Scholar 

  78. Barak A, et al. (2005) A phase I trial of stereotactic external beam radiation for subfoveal choroidal neovascular membranes in age-related macular degeneration. Br J Radiol 78 (933): 827-31

    Article  PubMed  CAS  Google Scholar 

  79. Flaxel CJ, et al. (2000) Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration. Eye (Lond) 14 ( Pt 2): 155-64

    Google Scholar 

  80. Bekkering GE, et al. (2009) The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review. Strahlenther Onkol 185(4): 211-21

    Article  PubMed  Google Scholar 

  81. Harding S, Sen J (2002) Percision low-dose proton beam radiotherapy of subfoveal choroidal neovascularization in age-related macular degeneration (abstract). Orlando: American Academy of Ophthalmology 281 (abstract)

    Google Scholar 

  82. Pharmacological Therapy for Macular Degeneration Study Group (1997) Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebocontrolled clinical trial. Arch Ophthalmol 115(7): 865-72

    Google Scholar 

  83. Bellmann C, et al. (2003) Visual acuity and contrast sensitivity in patients with neovascular age-related macular degeneration. Results from the Radiation Therapy for Age-Related Macular Degeneration (RAD-) Study. Graefes Arch Clin Exp Ophthalmol 241(12): 968-74

    Article  PubMed  Google Scholar 

  84. Finger PT, et al. (1999) Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. Am J Ophthalmol 127(2): 170-7

    Article  PubMed  CAS  Google Scholar 

  85. Berta A, Vamosi P (1995) Irradiation of macular subretinal neovascularization using Ruthenium applicators. Szemeset (Hung J Ophthalmol) (132): 67-75

    Google Scholar 

  86. Finger PT, et al. (2003) Palladium-103 plaque radiation therapy for macular degeneration: results of a 7 year study. Br J Ophthalmol 87(12): 1497-503

    Article  PubMed  CAS  Google Scholar 

  87. Jaakkola A, et al. (2005) Strontium plaque brachytherapy for exudative age-related macular degeneration: three-year results of a randomized study. Ophthalmology 112(4): 567-73

    Article  PubMed  Google Scholar 

  88. Avila MP, et al. (2009) Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina 29(2): 157-69

    Article  PubMed  Google Scholar 

  89. Avila MP, et al. (2009) Twelve-month short-term safety and visualacuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to agerelated macular degeneration. Br J Ophthalmol 93(3): 305-9

    Article  PubMed  CAS  Google Scholar 

  90. Avila MP, et al. (2009) Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD. Retina 29(2): 157-69

    Article  PubMed  Google Scholar 

  91. Macular Photocoagulation Study Group (1986) Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 104(5): 694-701

    Google Scholar 

  92. Macular Photocoagulation Study Group (1991) Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 109(9): 1220-31

    Google Scholar 

  93. Macular Photocoagulation Study Group (1994) Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 112(4): 480-8

    Google Scholar 

  94. Berger AS, Kaplan HJ (1992) Clinical experience with the surgical removal of subfoveal neovascular membranes. Short-term postoperative results. Ophthalmology 99(6): 969-75; discussion 975-6

    PubMed  CAS  Google Scholar 

  95. Thomas MA, et al. (1992) Surgical management of subfoveal choroidal neovascularization. Ophthalmology 99(6): 952-68; discussion 975-6

    PubMed  CAS  Google Scholar 

  96. Machemer R, Steinhorst UH (1993) Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 231(11): 635-41

    Article  PubMed  CAS  Google Scholar 

  97. Algvere PV, et al. (1994) Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Arch Clin Exp Ophthalmol 232(12): 707-16

    Article  PubMed  CAS  Google Scholar 

  98. Gillies MC, et al. (1993) Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b. Br J Ophthalmol 77(12): 759-65

    Article  PubMed  CAS  Google Scholar 

  99. Kirkpatrick JN, Dick AD, Forrester JV (1993) Clinical experience with interferon alfa-2a for exudative age-related macular degeneration. Br J Ophthalmol 77(12): 766-70

    Article  PubMed  CAS  Google Scholar 

  100. Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19(3): 361-72

    PubMed  Google Scholar 

  101. Alon T, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1(10): 1024-8

    Article  PubMed  CAS  Google Scholar 

  102. Emerson MV, Lauer AK (2007) Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. BioDrugs 21(4): 245-57

    Article  PubMed  CAS  Google Scholar 

  103. Nishijima K, et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171(1): 53-67

    Article  PubMed  CAS  Google Scholar 

  104. Schlingemann RO (2004) Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 242(1): 91-101

    Article  PubMed  CAS  Google Scholar 

  105. Shah GK, Sang DN, Hughes MS (2009) Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina 29(2): 133-48

    Article  PubMed  Google Scholar 

  106. Bergers G, et al. (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Journal of Clinical Investigation 111(9): 1287-95

    PubMed  CAS  Google Scholar 

  107. Bradley J, et al. (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10(2): 141-8

    Article  PubMed  CAS  Google Scholar 

  108. Jo N, et al. (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. American Journal of Pathology 168(6): 2036-53

    Article  PubMed  CAS  Google Scholar 

  109. Rogers AH, et al. (2002) Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. American Journal of Ophthalmology 134(4): 566-76

    Article  PubMed  Google Scholar 

  110. Schmidt-Erfurth U, et al. (2002) Histopathological changes following photodynamic therapy in human eyes. Archives of Ophthalmology 120(6): 835-44

    PubMed  Google Scholar 

  111. Spaide RF, et al. (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110(8): 1517-25

    Article  PubMed  Google Scholar 

  112. Spaide RF, et al. (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112(2): 301-4

    Article  PubMed  Google Scholar 

  113. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 117(10): 1329-45

    Google Scholar 

  114. Gillies MC, et al. (2004) Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Archives of Ophthalmology 122(3): 336-40

    Article  PubMed  CAS  Google Scholar 

  115. Rechtman E, et al. (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. British Journal of Ophthalmology 88(3): 344-7

    Article  PubMed  CAS  Google Scholar 

  116. Moshfeghi A, Puliafito C (2004) Combination verteporfin therapy and intravitreal triamcinolone n neovascular age-related macular degeneration. Meeting of the Retina Society. Baltimore, MD, USA

    Google Scholar 

  117. Roth D, Walsman S, Modi A, et al. (2004) Intravitreal triamcinolone combined with photodynamic therapy for exudative macular degeneration. Joint Meeting of the American Academy of Ophthalmology and European Society of Ophthalmology. New Orleans, LA, USA

    Google Scholar 

  118. Augustin A, Schmidt-Erfurth U (2004) PDT and triamcinolone for the treatment of occult CNV in AMD. in 27th Annual Macula Society Meeting. Las Vegas, NV, USA

    Google Scholar 

  119. El Matri L, Baklouti K, Mghaieth F, et al. (2004) Photodynamic therapy and intravitreal triamcinolone for exudative [sic] age related macular degeneration. Invest Ophthalmol Vis Sci 45(EAbstract): 3162

    Google Scholar 

  120. Johnson R, Yang S, McDonald HR, Ai E, Jumper JM (2004) Combined photodynamic therapy and intravitreal triamcinolone acetonide for AMD. Joint Meeting of the American Academy of Ophthalmology and European Society of Ophthalmology. New Orleans, LA, USA

    Google Scholar 

  121. Bhavsar A (2004) Combined verteporfin therapy and intravitreal triamcinolone in the treatment of minimally classic subfoveal CNV with or without RAP lesions. Joint Meeting of the American Academy of Ophthalmology and European Society of Ophthalmology. New Orleans, LA, USA

    Google Scholar 

  122. Spaide R, Sorenson J, Maranan L (2004) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone for juxtafoveal and extrafoveal choroidal neovascularization. Joint Meeting of the American Academy of Ophthalmology and European Society of Ophthalmology. New Orleans, LA, USA

    Google Scholar 

  123. Chan WM, et al. (2006) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. British Journal of Ophthalmology 90(3): 337-41

    Article  PubMed  Google Scholar 

  124. Ergun E, et al. (2006) Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. American Journal of Ophthalmology 142(1): 10-16

    Article  PubMed  CAS  Google Scholar 

  125. Arias L, et al. (2006) Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 113(12): 2243-50

    Article  PubMed  Google Scholar 

  126. Ruiz-Moreno JM, et al. (2007) Photodynamic therapy and highdose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina 27(4): 458-61

    Article  PubMed  Google Scholar 

  127. Maberley D, et al. (2009) Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. Ophthalmology 116(11): 2149-57.e1

    Article  PubMed  Google Scholar 

  128. Eyetech-Pharma (2004) Division of Anti-inflammatory, Analgesic and Ophthalmic Drug Products Advisory Committee Meeting Briefing Package for Macugen 2004. [cited 2010 04/28]; Available from: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053B1_02_FDA-Backgrounder.pdf

  129. Antoszyk AN, et al. (2008) Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology 145(5): 862-74

    Article  PubMed  CAS  Google Scholar 

  130. Lazic R, et al. (2007) Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 114(6): 1179-85

    Article  PubMed  Google Scholar 

  131. Kaiser PK, et al. (2007) Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular agerelated macular degeneration. Ophthalmology 116(4): 747-55

    Article  Google Scholar 

  132. Kaiser PK (2010) Combination therapy with verteporfin and anti-VEGF agents in neovascular age-related macular degeneration: where do we stand? British Journal of Ophthalmology 94(2): 143-5

    Article  PubMed  Google Scholar 

  133. QLT (2009) QLT Announces 12-month results from Novartis sponsored MONT BLANC Study evaluating standard-fluence VISUDYNE® combination therapy. [cited 2010 04/28]; Available from: http://www.qltinc.com/newsCenter/2009/090615.htm

  134. Augustin AJ, et al. (2007) Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 27(2): 133-40

    Article  PubMed  Google Scholar 

  135. Yip PP, et al. (2009) Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. British Journal of Ophthalmology 93(6): 754-8

    Article  PubMed  CAS  Google Scholar 

  136. Ehmann D, et al. (2007) Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). Canadian Journal of Ophthalmology 45(1): 36-40

    Article  Google Scholar 

  137. Bakri SJ, et al. (2009) Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 29(5): 573-8

    Article  PubMed  Google Scholar 

  138. Ahmadieh H, et al. (2007) Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmology 7: 10

    Article  PubMed  CAS  Google Scholar 

  139. Clinicaltrials.gov. (2010) Reduced Fluence Visudyne-Anti-VEGFDexamethasone In Combination for AMD Lesions (RADICAL). [cited 2010 04/28]; Available from: http://www.clinicaltrials.gov/ct2/show/NCT00492284

  140. Verin V, et al. (2007) Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The Dose-Finding Study Group. New England Journal of Medicine 344(4): 243-9

    Article  Google Scholar 

  141. Kirwan JF, et al. (2003) Beta irradiation: new uses for an old treatment: a review. Eye 17(2): 207-15

    Article  PubMed  CAS  Google Scholar 

  142. Wachsberger P, et al. (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clinical Cancer Research 9(6): 1957-71

    PubMed  CAS  Google Scholar 

  143. Bischof M, et al. (2004) Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. International Journal of Radiation Oncology, Biology, Physics 60(4): 1220-32

    Article  PubMed  CAS  Google Scholar 

  144. Avila MP, et al. (2009) Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. British Journal of Ophthalmology 93(3): 305-9

    Article  PubMed  CAS  Google Scholar 

  145. Dugel PU (2009) Radiation Therapy for Exudative AMD as an Operating Room Based Therapy, in Annual Meeting of the American Academy of Ophthalmology. San Francisco, CA

    Google Scholar 

  146. Brown DM, et al. (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine 355(14): 1432-44

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195, Cleveland, OH, USA

    Dr. Mark R. Barakat, Dr. Nathan Steinle & Prof. Dr. Peter K. Kaiser

Authors
  1. Dr. Mark R. Barakat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Nathan Steinle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Peter K. Kaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Barakat, M., Steinle, N., Kaiser, P. (2011). Kombinationstherapien zur Behandlung der AMD. In: Altersabhängige Makuladegeneration. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20870-6_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-20870-6_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-20869-0

  • Online ISBN: 978-3-642-20870-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation